Valuation
- Market cap
- 367,580,032,000
- Revenue TTM
- $76,450,350,000
- Net income TTM
- $15,542,030,000
- PE ratio
- 0.00
- Forward PE
- 18.12
- Profit margin
- 20.33%
- Debt to equity
- 1.00
Trading
- Volume
- 3,509,200
- Avg volume
- 2,766,894
- Day's range
- $57.00 – $57.89
- Shares out
- 6,370,538,000
- Stochastic %K
- 76%
- Beta
- 0.44
- Analysts
- Sell
- Price target
- $52.72
Company profile
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It als...
Show more
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- Phone
- 41 61 688 88 80
- Website
- https://www.roche.com
- Address
- Grenzacherstrasse 124, Basel, Switzerland
Latest news
No headlines yet.
